Trial · NCT01431521
Results by group15
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 15 of 15
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Percent Change From Baseline in Hepatic Fat | MK-4074 | -35.73 | 95% Confidence Interval -44.53 to -26.93 | Percent change | |
| Percent Change From Baseline in Hepatic Fat | Pioglitazone | -18.04 | 95% Confidence Interval -26.84 to -9.24 | Percent change | |
| Percent Change From Baseline in Hepatic Fat | Placebo | 8.63 | 95% Confidence Interval -0.17 to 17.43 | Percent change | |
| Percent Change From Baseline in Alanine Transaminase (ALT) | MK-4074 | -9.82 | 95% Confidence Interval -21.13 to 1.49 | Percent change | |
| Percent Change From Baseline in Alanine Transaminase (ALT) | Pioglitazone | -20.21 | 95% Confidence Interval -31.52 to -8.90 | Percent change | |
| Percent Change From Baseline in Alanine Transaminase (ALT) | Placebo | -3.47 | 95% Confidence Interval -15.08 to 8.13 | Percent change | |
| Percent Change From Baseline Aspartate Transaminase (AST) | MK-4074 | -6.74 | 95% Confidence Interval -19.73 to 6.24 | Percent change | |
| Percent Change From Baseline Aspartate Transaminase (AST) | Pioglitazone | -13.95 | 95% Confidence Interval -26.93 to -0.97 | Percent change | |
| Percent Change From Baseline Aspartate Transaminase (AST) | Placebo | -3.28 | 95% Confidence Interval -16.64 to 10.08 | Percent change | |
| Number of Participants Experiencing One or More Adverse Events (AE) | MK-4074 | 4 | Participants | ||
| Number of Participants Experiencing One or More Adverse Events (AE) | Pioglitazone | 4 | Participants | ||
| Number of Participants Experiencing One or More Adverse Events (AE) | Placebo | 5 | Participants | ||
| Number of Participants Who Discontinued Study Drug Due to an AE | MK-4074 | 0 | Participants | ||
| Number of Participants Who Discontinued Study Drug Due to an AE | Pioglitazone | 0 | Participants | ||
| Number of Participants Who Discontinued Study Drug Due to an AE | Placebo | 0 | Participants |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT01431521/results